A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies

Neuropsychopharmacology

Volumn 27, Issue 6, 2002, Pages 980-992

  Moore, Holly ^a,b   Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anandamide; Apomorphine; Carbenoxolone; Gap junction; Grooming; Motor activity; Oral behaviors; Sniffing stereotypy

Indexed keywords

ANANDAMIDE; APOMORPHINE; CARBENOXOLONE; DOPAMINE RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; COMPARATIVE STUDY; CONDUCTANCE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GAP JUNCTION; GROOMING; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SNIFFING; STEREOTYPY;

ANIMALS; APOMORPHINE; CARBENOXOLONE; CORPUS STRIATUM; GAP JUNCTIONS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; STEREOTYPED BEHAVIOR;

EID: 0036900189     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00383-4     Document Type: Article

References (74)

1. Abrams D.R., Bruno J.P. Ontogeny of apomorphine-induced stereotypy and its D1 and D2 receptor mediation in rats depleted of dopamine as neonates. Dev Psychobiol. 25:1992;475-495.
2. Aceto M.D., Scates S.M., Razdan R.K., Martin B.R. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther. 287:1998;598-605.
3. Aldridge J.W., Berridge K.C. Coding of serial order by neostriatal neurons. a "natural action" approach to movement sequence J Neurosci. 18:1998;2777-2787.
4. Aldridge J.W., Berridge K.C., Herman M., Zimmer L. Neuronal coding of serial order. syntax of grooming in the neostriatum Psyhcological Sciences. 4:1993;391-395.
5. Alvarez-Maubecin V., Garcia-Hernandez F., Williams J.T., Van Bockstaele E.J. Functional coupling between neurons and glia. J Neurosci. 20:2000;4091-4098.
6. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 58:1999;315-348.
7. Armanini D., Karbowiak I., Krozowski Z., Funder J.W., Adam W.R. The mechanism of mineralocorticoid action of carbenoxolone. Endocrinology. 111:1982;1683-1686.
8. Bannerman P., Nichols W., Puhalla S., Oliver T., Berman M., Pleasure D. Early migratory rat neural crest cells express functional gap junctions. evidence that neural crest cell survival requires gap junction function J Neurosci Res. 61:2000;605-615.
9. Belluardo N., Mudo G., Trovato-Salinaro A., Le Gurun S., Charollais A., Serre-Beinier V., Amato G., Haefliger J.A., Meda P., Condorelli D.F. Expression of connexin36 in the adult and developing rat brain. Brain Res. 865:2000;121-138.
10. Beninger R.J., Mazurski E.J., Hoffman D.C. Receptor subtype-specific dopaminergic agents and unconditioned behavior. Pol J Pharmacol Pharm. 43:1991;507-528.
11. Bennett S.A., Arnold J.M., Chen J., Stenger J., Paul D.L., Roberts D.C. Long-term changes in connexin32 gap junction protein and mRNA expression following cocaine self-administration in rats. Eur J Neurosci. 11:1999;3329-3338.
12. Berger H.J., van Hoof J.J., van Spaendonck K.P., Horstink M.W., van den Bercken J.H., Jaspers R., Cools A.R. Haloperidol and cognitive shifting. Neuropsychologia. 27:1989;629-639.
13. Berridge K.C., Aldridge J.W. Super-stereotypy I. enhancement of a complex movement sequence by systemic dopamine D1 agonists Synapse. 37:2000;194-204. a.
14. Berridge K.C., Aldridge J.W. Super-stereotypy II. enhancement of a complex movement sequence by intraventricular dopamine D1 agonists Synapse. 37:2000;205-215. b.
15. Boger D.L., Sato H., Lerner A.E., Guan X., Gilula N.B. Arachidonic acid amide inhibitors of gap junction cell-cell communication. Bioorg Med Chem Lett. 9:1999;1151-1154.
16. Bou-Flores C., Berger A.J. Gap junctions and inhibitory synapses modulate inspiratory motoneuron synchronization. J Neurophysiol. 85:2001;1543-1551.
17. Braun A.R., Chase T.N. Obligatory D1/D2 receptor interaction in the generation of dopamine agonist related behaviours. Eur J Pharmacol. 131:1986;301-306.
18. Byrnes E.M., Abrams D., Bruno J.P. Co-activation of D1- and D2-like receptors is unnecessary for stimulated motor behavior in rats depleted of dopamine during development. Behav Brain Res. 61:1994;205-214.
19. Cameron D.L., Crocker A.D. Localization of striatal dopamine receptor function by central injection of an irreversible receptor antagonist. Neuroscience. 32:1989;769-778.
20. Cepeda C., Walsh J.P., Hull C.D., Howard S.G., Buchwald N.A., Levine M.S. Dye-coupling in the neostriatum of the rat. I. Modulation by dopamine-depleting lesions Synapse. 4:1989;229-237.
21. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20:2001;7033-7040.
22. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain. 124:2001;2503-2512.
23. Costa B., Vailati S., Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol. 10:1999;327-331.
24. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav. 46:1993;967-972.
25. Cromwell H.C., Berridge K.C. Implementation of action sequences by a neostriatal site. a lesion mapping study of grooming syntax J Neurosci. 16:1996;3444-3458.
26. Cromwell H.C., Berridge K.C., Drago J., Levine M.S. Action sequencing is impaired in D1A-deficient mutant mice. Eur J Neurosci. 10:1998;2426-2432.
27. Davidkova G., Zhou L.W., Morabito M., Zhang S.P., Weiss B. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing up-regulation of D2 dopamine receptors. J Pharmacol Exp Ther. 285:1998;1187-1196.
28. Davidson J.S., Baumgarten I.M. Glycyrrhetinic acid derivatives. a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships J Pharmacol Exp Ther. 346:1988;1104-1107.
29. De Petrocellis L., Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., Creminon C., Davis J.B., Geppetti P., Di Marzo V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem. 77:2001;1660-1663.
30. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 95:1998;8375-8380.
31. Delfs J.M., Kelley A.E. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Neuroscience. 39:1990;59-67.
32. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice. evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain J Neurochem. 75:2000;2434-2444.
33. Downes R.P., Waddington J.L. Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur J Pharmacol. 234:1993;135-136.
34. Fowler S.C., Liou J.R. Microcatalepsy and disruption of forelimb usage during operant behavior. differences between dopamine D1 (SCH-23390) and D2 (raclopride) antagonists Psychopharmacology (Berl). 115:1994;24-30.
35. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 231:1993;313-314.
36. Garcia N. Jr., Jarai Z., Mirshahi F., Kunos G., Sanyal A.J. Systemic and portal hemodynamic effects of anandamide. Am J Physiol Gastrointest Liver Physiol. 280:2001;G14-G20.
37. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 263:1992;E1125-E1130.
38. Horikawa H.P., Nakazato T., Hikosaka O. Duration of catalepsy correlates with increased intrastriatal sulpiride. Eur J Pharmacol. 326:1997;15-21.
39. Hymas N., Lees A., Bolton D., Epps K., Head D. The neurology of obsessional slowness. Brain. 114:1991;2203-2233.
40. Jaspers R.M., de Vries T.J., Cools A.R. Effects of intrastriatal apomorphine on changes in switching behaviour induced by the glutamate agonist AMPA injected into the cat caudate nucleus. Behav Brain Res. 37:1990;247-254.
41. Jefferys J.G. Nonsynaptic modulation of neuronal activity in the brain. electric currents and extracellular ions Physiol Rev. 75:1995;689-723.
42. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
43. Koene P., Prinssen E.P., Cools A.R. Involvement of the nucleus accumbens in oral behaviour in the freely moving rat. Eur J Pharmacol. 233:1993;151-156.
44. Mashurano M., Waddington J.L. Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393. Neuropharmacology. 25:1986;947-949.
45. Matsumoto N., Hanakawa T., Maki S., Graybiel A.M., Kimura M. Role of [corrected] nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner. J Neurophysiol. 82:1999;978-998.
46. Molloy A.G., Waddington J.L. Dopaminergic behavior stereospecific promoted by the D1 agonist SKF 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology (Berl). 82:1984;409-410. a.
47. Molloy A.G., Waddington J.L. Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology (Berl). 82:1984;409-410. b.
48. O'Donnell P., Grace A.A. Cortical afferents modulate striatal gap junction permeability via nitric oxide. Neuroscience. 76:1997;1-5.
49. Onn S.P., Grace A.A. Dye coupling between rat striatal neurons recorded in vivo. compartmental organization and modulation by dopamine J Neurophysiol. 71:1994;1917-1934.
50. Onn S.P., Grace A.A. Repeated treatment with haloperidol and clozapine exerts differential effects on dye coupling between neurons in subregions of striatum and nucleus accumbens. J Neurosci. 15:1995;7024-7036.
51. Onn S.P., Grace A.A. Alterations in electrophysiological activity and dye coupling of striatal spiny and aspiny neurons in dopamine-denervated rat striatum recorded in vivo. Synapse. 33:1999;1-15.
52. Onn S.P., Grace A.A. Amphetamine withdrawal alters bistable states and cellular coupling in rat prefrontal cortex and nucleus accumbens neurons recorded in vivo. J Neurosci. 20:2000;2332-2345.
53. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2nd ed:1996;Academic Press, San Diego, CA.
54. Pedro B.M., Pilowsky L.S., Costa D.C., Hemsley D.R., Ell P.J., Verhoeff N.P., Kerwin R.W., Gray N.S. Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia. Psychol Med. 24:1994;423-429.
55. Peinado A., Yuste R., Katz L.C. Gap junctional communication and the development of local circuits in neocortex. Cereb Cortex. 3:1993;488-498.
56. Perez Velazquez J.L., Carlen P.L. Gap junctions, synchrony and seizures. Trends Neurosci. 23:2000;68-74.
57. Ridley R.M. The psychology of perserverative and stereotyped behaviour. Prog Neurobiol. 44:1994;221-231.
58. Roberts N.B., Taylor W.H. The actions of carbenoxolone on enzymes and their relation to its therapeutic effect. Scand J Gastroenterol Suppl. 65:1980;11-17.
59. Roerig B., Feller M.B. Neurotransmitters and gap junctions in developing neural circuits. Brain Res Brain Res Rev. 32:2000;86-114.
60. Romero J., Garcia L., Cebeira M., Zadrozny D., Fernandez-Ruiz J.J., Ramos J.A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior. role of nigrostriatal dopaminergic neurons Life Sci. 56:1995;2033-2040.
61. Rothwell J.C. Physiology and anatomy of possible oscillators in the central nervous system. Mov Disord. 13:1998;24-28.
62. Rozental R., Srinivas M., Spray D.C. How to close a gap junction channel. efficacies and potencies of uncoupling agents Giaume C. Connexin Methods and Protocols (Methods in Molecular Biology). 2001;447-476 Humana Press, Totowa, NJ.
63. Sanudo-Pena M.C., Tsou K., Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65:1999;703-713.
64. Schmidt W.J. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology (Berl). 90:1986;123-130.
65. Schweighofer N., Doya K., Kawato M. Electrophysiological properties of inferior olive neurons. A compartmental model J Neurophysiol. 82:1999;804-817.
66. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Ann Rev Pharmacol Toxicol. 39:1999;313-341.
67. Stein E.A., Fuller S.A., Edgemond W.S., Campbell W.B. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology. 19:1998;481-491.
68. Stewart P.M., Wallace A.M., Atherden S.M., Shearing C.H., Edwards C.R. Mineralocorticoid activity of carbenoxolone. contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man Clinical Science. 78:1990;49-54.
69. Sullivan E.V., Fama R., Shear P.K., Cahn-Weiner D.A., Stein M., Zipursky R.B., Pfefferbaum A. Motor sequencing deficits in schizophrenia. a comparison with Parkinson's disease Neuropsychology. 15:2001;342-350.
70. Szechtman H., Culver K., Eilam D. Role of dopamine systems in obsessive-compulsive disorder (OCD). implications from a novel psychostimulant-induced animal model Pol J Pharmacol. 51:1999;55-61.
71. van den Pol A.N., Dudek F.E. Cellular communication in the circadian clock, the suprachiasmatic nucleus. Neuroscience. 56:1993;793-811.
72. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
73. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci. 20:2000;8305-8314.
74. White R., Ho W.S., Bottrill F.E., Ford W.R., Hiley C.R. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol. 134:2001;921-929.